Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal

[cafead]

via Concerns are mounting about the safety of Eisai and Biogen’s Alzheimer’s disease prospect lecanemab. Ahead of the presentation of the full phase 3 dataset on Tuesday, Science has reported on the death of a second recipient of the anti-amyloid antibody who suffered a brain hemorrhage.

article source